Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus

Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:FEBS Open Bio
Hlavní autoři: Nishio, Eiji, Hayashi, Takanori, Akaza, Mao, Hisatomi, Yukiko, Hikichi, Masahiro, Fujii, Takuma, Utsumi, Toshiaki, Harada, Nobuhiro, Shimono, Yohei
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7530388/
https://ncbi.nlm.nih.gov/pubmed/32810922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12956
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky